All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
China’s NMPA granted conditional approval for a COVID-19 oral pill to treat adult patients with mild to moderate cases of the virus to a unit of Guangdong Zhongsheng Pharmaceutical Co. Ltd.
Biohaven Ltd. has acquired global rights, excluding China, from Highlightll Pharmaceutical Co. Ltd. to develop and commercialize a dual inhibitor of tyrosine kinase 2 (TYK2) and JAK1, BHV-8000 (TLL-041), for the treatment of brain disorders in a deal worth up to $970 million.
CSPC Pharmaceutical Group Ltd.’s COVID-19 mRNA vaccine, SYS-6006, has been included for emergency use by the NMPA, the company said on March 22, marking the first domestically developed COVID-19 mRNA vaccine approved for use in China.
The increased availability of capital, greater access to talent, strong local governmental support and more focused attention on IP issues have increased the complexity of deals taking place between biotech and big pharma companies in China, according to Michelle Chan, chief business officer of Insilico Medicine Inc.
Triastek Inc., a digital pharmaceutical solutions company, is taking a unique approach by using 3D printing technology to develop a pipeline that spans rheumatoid arthritis (RA), clotting disorders, ulcerative colitis and pulmonary hypertension. Its technology was recently validated through a partnership with Boehringer Ingelheim GmbH. The company’s 3D printing products include T-19, T-20 and T-21, which have all received IND approval from the FDA.
Beijing Vas Medical Co. Ltd. raised ¥100 million (US$15M) in an angel financing round as well as obtaining marketing approval from China’s NMPA for its vascular interventional surgery robot. The company plans to use the funds to develop technology, update products, expand its team and make promotions.
China’s NMPA granted conditional approval for a COVID-19 oral pill to treat adult patients with mild to moderate cases of the virus to a unit of Guangdong Zhongsheng Pharmaceutical Co. Ltd. RAY-1216 is a peptidomimetic inhibitor of SARS-CoV-2 main protease (Mpro), which is also known as a 3C-like protease (3CLpro).
The increased availability of capital, greater access to talent, strong local governmental support and more focused attention on IP issues have increased the complexity of deals taking place between biotech and big pharma companies in China, according to Michelle Chan, chief business officer of Insilico Medicine Inc, who spoke in a panel discussion on the topic of Asia-Pacific partnering at this year’s Bio-Europe Spring, in Basel, Switzerland on March 21.
Detection Technology plc has agreed to acquire X-ray flat panel detector provider Shanghai Haobo Imaging Technology Co. Ltd. to expand in the thin-film transistor (TFT) flat panel detector market. Shanghai-based Haobo Imaging was valued at around €14 million (US$15 million). Finland-based Detection Technology will acquire a 90% stake in the Chinese company while Haobo Imaging’s founder and management will maintain 10% of the shares.
Yongrenxin Medical Instrument Co. Ltd. raised nearly $100 million in a series A funding round to build a health platform to treat heart failures. Sinovac Biotech Ltd. led the round.
RSS
